Management describes the Precision Medicine segment as a strategic engine that validates therapeutic targets and builds physician relationships rather than just a cash generator. The company has pivoted toward an internal innovation model for R&D to capture higher value, citing the high market premiums paid for early-stage radiopharmaceutical assets. Vertical integration through over $0.5 billion in infrastructure investment is viewed as a critical moat due to the complex logistics and short shelf lif ...

Launching two additional products pending regulatory outcomes: Pixclara (Pixlumia in Europe) for glioblastoma and Zircaix for renal cancer.Continuing to grow approved products, including building on the launch of Gozetotide and the FDA approval of Gleolan in 2025.He also said the precision medicine business is more than a cash generator, calling it strategic validation of therapeutic targets, a way to streamline clinical trials, and an avenue to deepen relationships with physician stakeholders. Looking ahea ...

Financial Data and Key Metrics Changes - The company reported a 56% growth in revenue to $804 million, marking its third consecutive year of double-digit revenue growth [17][19] - EBITDA improved by 25% to $216 million, driven by strong demand for Illuccix and the launch of Gleolan [19][23] - The gross margin remained stable at 53%, with a significant portion of gross margin generated from the precision medicine business [22][23] Business Line Data and Key Metrics Changes - Revenue from the precision medicine business increased by 22% year-over-year, contributing an additional $113 million [19][23] - The precision medicine business generated approximately $400 million in gross margin, with 94% of the gross margin coming from this segment [20][23] - Investments in product development totaled $157 million, focusing on late-stage pipeline projects [22] Market Data and Key Metrics Changes - The precision medicine portfolio delivered $622 million in revenue, with sequential growth every quarter, even during challenging market conditions [30] - The company is expanding its market presence, with Illuccix now available in 17 countries and marketing authorizations in over 24 markets [35] Company Strategy and Development Direction - The company aims to transition to a high-value therapeutic business, with planned R&D investments ranging from $200 million to $240 million in 2026 [26] - A dual product strategy for Illuccix and Gleolan is in place to manage economic needs and reimbursement preferences effectively [58][60] - The company is focused on expanding its product offerings, indications, and geographical reach, particularly in key markets like the U.K., Germany, and China [35][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving approximately 20% revenue growth in 2026, with guidance set at $950 million to $970 million [28][29] - The company is committed to reinvesting earnings into R&D and commercial growth rather than optimizing near-term earnings per share [68] - Management highlighted the importance of clinical credibility and operational reliability in sustaining market leadership [32][33] Other Important Information - The company has over 30 sponsored and collaborative studies running, with four major trials expected to generate significant data this year [47] - The ProstACT Global study is progressing well, with recruitment for part two ramping up [48][49] Q&A Session Questions and Answers Question: When might we see data for 591, the safety data? - The company is completing clinical case report forms and will disclose the data simultaneously with the FDA submission, with no delays expected from the FDA side [54][56] Question: Can you elaborate on the early performance of the two-product strategy for Illuccix and Gleolan? - The two-product strategy allows the company to manage economic needs and reimbursement preferences effectively, adapting to changes in the reimbursement environment [58][60] Question: Will the company reinvest earnings to achieve close to zero NPAT for F-26, F-27, and F-28? - The company will reinvest the majority of earnings back into R&D and commercial growth, with no profit objective for the next two years [68] Question: How much growth in precision medicine revenue is coming from markets outside of the U.S.? - Currently, 95% of revenue is U.S.-based, but the company expects this mix to change as it expands into other markets like Japan [74]

Financial Data and Key Metrics Changes - The company reported a 56% growth in revenue to AUD 804 million, marking its third consecutive year of double-digit revenue growth [18][20] - EBITDA improved by 25% to AUD 216 million, driven by strong demand for Illuccix and the launch of Gozellix [20][23] - The gross margin remained stable at 53%, with 94% of gross margin generated from the precision medicine business [21][22] Business Line Data and Key Metrics Changes - Revenue from the precision medicine business increased by 22% year-over-year, contributing an additional AUD 113 million [20][23] - The precision medicine business demonstrated a 28% increase in operating profit and a 25% increase in EBITDA [23] - The company invested AUD 157 million into product development, focusing on its late-stage pipeline [22] Market Data and Key Metrics Changes - The precision medicine portfolio generated AUD 622 million in revenue, up 22% year-over-year, with sequential growth every quarter [31] - Illuccix is now available in 17 countries with reimbursement secured, and marketing authorizations in over 24 markets [35] - The company anticipates a 25% growth in its precision medicine business for 2026, driven by the full year of RLS revenue [28] Company Strategy and Development Direction - The company aims to transition to a high-value therapeutic business, with planned R&D investment in the range of AUD 200 million to AUD 240 million for 2026 [26] - The focus will remain on reinvesting revenues back into the business rather than optimizing near-term earnings per share [26][72] - The company is committed to building long-term value through disciplined capital allocation and strategic investments in R&D and commercial performance [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another year of roughly 20%+ revenue growth in 2026, with guidance set at AUD 950 million to AUD 970 million [28][30] - The company is focused on executing its strategic plan to grow the precision medicine business by expanding product offerings and geographic reach [35] - Management acknowledged the challenges faced with regulatory approvals but emphasized the importance of learning from these experiences to enhance future submissions [15][72] Other Important Information - The company has over 30 sponsored and collaborative studies running, with four major trials highlighted as priorities for the year [49] - The ProstACT Global study is currently recruiting for part two, with results expected to be released soon [50] - The company has made extensive changes to its management team and regulatory affairs capabilities to improve future product submissions [15] Q&A Session Summary Question: When might data for 591 be available? - Management indicated that the company is not waiting on the FDA and will disclose data as soon as it is available [56][58] Question: Insights on the two-product strategy for Illuccix and Gozellix? - The two-product strategy allows the company to manage economic needs and preferences of different customer types, adapting to changes in reimbursement environments [61][62] Question: Clarification on reinvesting earnings for future years? - Management confirmed that the majority of earnings will be reinvested back into the company for growth, particularly in R&D and commercial development [72] Question: Growth contribution from markets outside the US? - Currently, 95% of revenue is US-based, but the company expects this mix to change as it expands into other markets [78] Question: Will R&D spending be adjusted based on commercial performance? - Management stated that R&D investment is discretionary and can be adjusted based on commercial performance, focusing on priority studies [75][76]

Telix Pharmaceuticals (NasdaqGS:TLX) H2 2025 Earnings call February 19, 2026 05:30 PM ET Speaker13Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Kyahn Williamson, SVP of Investor Relations and Corporate Communications. Please go ahead.Speaker9Thank you, and thank you to everybody for joining us on this call this morning, this evening, wherever you are in the world. We launched our annual report and full year results on the ASX ...

Full Year Results Presentation For personal use only February 20, 2026 ASX: TLX | NASDAQ: TLX - FY 2025 treatment 18 F -FET scan published in EJNMMI showing a patient with recurrent glioblastoma (GBM) who experienced a near -complete response following treatment with TLX101 -Tx (Iodofalan (¹³¹I), [¹³¹I]IPA), Telix's investigational LAT1 -targeted therapy. Patient representative scans, individual results may vary. Post - treatment Pre Presenters Agenda For personal use only Kyahn Williamson SVP Investor Rela ...

Core Insights - Telix Pharmaceuticals reported fiscal 2025 revenue of approximately $804 million, meeting its upgraded guidance of $800-$820 million [1] - The company experienced a significant 46% year-over-year increase in fourth quarter revenue, totaling around $208 million [2] - The Precision Medicine business generated approximately $161 million in revenue, reflecting a 4% quarter-over-quarter growth driven by the successful U.S. launch of Gozellix [2] Financial Performance - Fiscal 2025 revenue was approximately $804 million, aligning with guidance [1] - Fourth quarter revenue increased by 46% year-over-year to around $208 million [2] - Precision Medicine revenue was approximately $161 million, with a 4% quarter-over-quarter growth [2] Clinical Advancements - The company is advancing clinical studies, including the ProstACT Global Phase 3 study and the SOLACE Phase 1 study in the U.S. [3] - Telix dosed the first patient in the U.S. for the BiPASS Phase 3 trial to evaluate its PSMA-PET imaging agents [4] Strategic Collaborations - Telix announced a strategic collaboration with Varian to explore the combination of its radiopharmaceuticals with external beam radiation therapy [5] Stock Performance - Telix stock is currently trading 5.5% below its 20-day simple moving average and 22.6% below its 100-day SMA, indicating a bearish trend [6] - Over the past 12 months, shares have decreased by 56.91% [6] - The stock carries a Buy Rating with an average price target of $21.20, despite trading at a premium P/E multiple [8] Analyst Insights - Analysts view the shift from a diagnostic-focused business to a pure-play radiopharmaceutical company as a positive development [9] - The bull case for Telix is based on the potential for durable cash flows from Illuccix and Gozellix [9] Market Position - Telix Pharmaceuticals' Benzinga Edge scorecard indicates a challenging outlook, with low momentum and a premium value score [10] - The stock was down 6.86% at $7.20 at the time of publication [11]

MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Q4 2025 Highlights Full-year (FY) 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion1), in line with upgraded guidance of US$800-$820 million2 (previously US$770-800 million).Q4 2025 unaudited Group revenue of approximately US$208 mill ...

Core Viewpoint - Telix Pharmaceuticals has initiated the BiPASS™ Phase 3 trial in the U.S. to evaluate the effectiveness of its PSMA-PET imaging agents, Illuccix® and Gozellix®, in improving prostate cancer diagnosis and reducing unnecessary biopsies [1][2][4]. Group 1: BiPASS™ Trial Overview - BiPASS™ is the first study aimed at obtaining marketing authorization for Ga-PSMA-PET imaging in the pre-biopsy setting, enrolling 250 patients across the U.S. and Australia [2][3]. - The trial seeks to determine if combining MRI with Illuccix/Gozellix can enhance diagnostic accuracy and minimize unnecessary biopsies compared to current practices [2][3]. Group 2: Prostate Biopsy Context - Over one million prostate biopsies are conducted annually in the U.S., with up to 75% yielding negative results, and one in four patients opting out of the procedure [3]. - The BiPASS™ study aims to improve lesion detection and patient stratification by integrating non-invasive imaging early in the diagnostic process, potentially leading to fewer biopsies or more precise ones [3][4]. Group 3: Potential Impact - If successful, the BiPASS™ study could significantly reduce unnecessary biopsies, enhance patient experience, and broaden access to precision imaging for suspected prostate cancer patients [4][5]. - The trial aligns with Telix's commitment to clinical innovation and patient-centric approaches, aiming to eliminate invasive biopsy procedures [5]. Group 4: Company Background - Telix Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals, headquartered in Melbourne, Australia, with operations in multiple countries [23]. - The company is developing a portfolio of products to address unmet medical needs in oncology and rare diseases, with Illuccix and Gozellix already transforming prostate cancer management [23][24].

Summary of Cardinal Health Conference Call Company Overview - **Company**: Cardinal Health - **Industry**: Healthcare Services - **CEO**: Jason Hollar - **CFO**: Aaron Alt - **Revenue**: Expected to exceed $250 billion in the current year [5][6] Key Financial Highlights - **Earnings Per Share (EPS)**: Expected to be at least $10 per share for fiscal 2026, driven by broad-based growth and strategic initiatives [3][14] - **Core Operating Earnings Growth**: Achieved a 14% CAGR over the last several years, translating into an 18% EPS growth [4] - **Adjusted Free Cash Flow**: Averaging over $3 billion, with a conversion rate of over 150% over the last three years [6] - **Pharmaceutical and Specialty Solutions Business**: Accounts for over 90% of revenue and nearly 80% of profit [6] Strategic Focus Areas - **Core Business**: Emphasis on pharmaceutical and specialty solutions, with a focus on organic and inorganic growth [15][16] - **At-Home Solutions**: Growth in this segment is seen as a strategic priority, with investments in technology and partnerships [11][60] - **GMPD (Medical Supply Division)**: Positioned as a turnaround business, with significant investments to improve performance and service levels [62][64] Market Dynamics - **Demographics**: Increasing number of Americans over 65 years old, leading to higher pharmaceutical utilization [10] - **Utilization Trends**: Strong demand across various product categories, with a focus on maintaining low unit costs [9][32] - **Pricing Environment**: Contractual ability to renegotiate prices in response to market changes, with a focus on maintaining margins [28][30] Growth Opportunities - **Specialty Areas**: Focus on autoimmune, urology, and oncology, with significant growth expected in these therapeutic areas [19][20] - **Biopharma Solutions**: Anticipated growth of over 30% in fiscal 2026, with plans to achieve $1 billion in revenue by fiscal 2028 [21][22] - **M&A Strategy**: Focus on tuck-in acquisitions to enhance existing capabilities, particularly in specialty areas [66][67] Risks and Challenges - **Regulatory Changes**: Potential impacts from CMMI demos and pricing changes related to Part B, but manageable due to the diversified payer mix [34][35] - **Market Competition**: Continuous investment in capabilities to maintain competitive advantage and customer relationships [13][40] Conclusion - **Overall Outlook**: Cardinal Health is positioned for continued growth with a strong focus on strategic initiatives, operational improvements, and market opportunities. The company remains committed to delivering value to shareholders while navigating industry challenges [68]